After a good third quarter: Bayer confirms Group outlook
Net income more than doubled to EUR 642 million (plus 125.3 percent)
Sales of the Bayer Group rose by 1.0 percent in the third quarter to EUR 8,670 million (Q3 2010: EUR 8,581 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 4.8 percent. Sales in the emerging markets rose by 9.5 percent on a currency-adjusted (Fx adj.) basis and accounted for a disproportionately large share of growth. The operating result (EBIT) advanced by a substantial 94.9 percent to EUR 1,099 million (Q3 2010: EUR 564 million).
Special charges totaled EUR 75 million (Q3 2010: EUR 436 million), including restructuring expenses of EUR 69 million. Earnings in the prior-year quarter were diminished by provisions for litigations concerning genetically modified rice (LL RICE) in the United States.
EBIT before special items climbed by 17.4 percent to EUR 1,174 million (Q3 2010: EUR 1,000 million). Earnings before interest, taxes, depreciation and amortization (EBITDA) – before special items – rose by 8.5 percent to EUR 1,805 million (Q3 2010: EUR 1,664 million). Net income more than doubled, increasing by 125.3 percent to EUR 642 million (Q3 2010: EUR 285 million). Core earnings per share rose by 17.9 percent to EUR 1.12 (Q3 2010: EUR 0.95).
Gross cash flow climbed by 49.6 percent to EUR 1,327 million (Q3 2010: EUR 887 million) due to the improved operating income and lower special charges, while net cash flow was level year on year at EUR 1,577 million (Q3 2010: EUR 1,555 million). Despite negative currency effects of approximately EUR 0.3 billion, net financial debt as of September 30 declined by EUR 0.4 billion compared with June 30, 2011, to EUR 7.0 billion.
Higher earnings at HealthCare
Sales of the HealthCare subgroup receded by 1.7 percent in the third quarter, to EUR 4,200 million (Q3 2010: EUR 4,271 million), due to negative currency effects. After adjusting for currency and portfolio effects, sales rose by 1.6 percent. “The trend in the pharmaceuticals business in the emerging markets was particularly encouraging,” Dekkers said. On the other hand, pharmaceuticals sales were down in Europe and North America. The consumer health business developed positively in all regions on a currency-adjusted basis.
Sales in the Pharmaceuticals segment rose by 0.3 percent (Fx & portfolio adj.) to EUR 2,663 million, mainly on account of the positive development in Asia/Pacific and Latin America, especially China and Brazil. In North America and Western Europe, however, business continued to be held back by health system reforms. Among the segment’s top products, the YAZ™ family of oral contraceptives developed particularly well. Sales of this product group advanced by 16.5 percent (Fx adj.) compared with a weak prior-year quarter. Double-digit growth was also posted by Aspirin™ Cardio for the prevention of heart attacks, with sales rising by 11.4 percent (Fx adj.). Sales of the cancer drug Nexavar™ rose by 4.5 percent (Fx adj.), mainly for the liver cancer indication. By contrast, sales of the blood-clotting drug Kogenate™ declined by 3.9 percent (Fx adj.) due to fluctuations in the ordering schedule of the distribution partner. In addition, the partial reorganization of distribution for general medicine products in the United States resulted in a 31.0 percent (Fx adj.) decline in sales of the erectile dysfunction treatment Levitra™ compared with the strong prior-year quarter.
Sales in the Consumer Health segment improved by 3.8 percent (Fx & portfolio adj.) to EUR 1,537 million. All regions contributed to growth, especially Latin America/Africa/ Middle East. In the non-prescription medicines business (Consumer Care), we saw sales gains particularly for the Bepanthen™/Bepanthol™ line of skincare products (Fx adj. plus 5.2 percent) and the pain-reliever Aspirin™ (Fx adj. plus 3.0 percent). The Medical Care Division benefited mainly from growth in the diabetes care business, with the Contour™ line of blood glucose meters gaining 11.2 percent (Fx adj.). By contrast, the animal health business stagnated at the prior-year level. Sales of the Advantage™ line of flea, tick and worm control products receded by 6.6 percent (Fx adj.).
EBITDA before special items of HealthCare improved by 9.3 percent to EUR 1,226 million (Q3 2010: EUR 1,122 million). The underlying EBITDA margin thus rose to 29.2 percent (Q3 2010: 26.3 percent). Earnings were driven by the pharmaceuticals business, where costs were lower in all functions. “This shows our efficiency programs are starting to bear fruit,” said Dekkers. In addition, earnings were buoyed by lower development costs following the successful completion of most Phase III studies for the anticoagulant Xarelto™. Health system reforms and negative currency changes, however, had a negative effect.
CropScience significantly improves sales and earnings
The CropScience subgroup raised sales by 2.8 percent (Fx & portfolio adj. 9.4 percent) to EUR 1,379 million (Q3 2010: EUR 1,341 million). While business at Crop Protection expanded thanks to substantially higher volumes, sales were down at BioScience and Environmental Science. “A positive factor was the favorable market environment, with high prices for agricultural raw materials,” Dekkers explained. The subgroup posted substantial growth in sales in the Latin America/Africa/Middle East and Asia/Pacific regions, where business expanded by 13.8 and 12.5 percent, respectively, on a currency-adjusted basis. CropScience also made modest gains in Europe and North America, where sales rose by 2.3 and 2.2 percent, respectively.
In the Crop Protection segment, all product groups delivered encouraging growth. The seed treatment business in particular advanced substantially, with sales up by 35.1 percent (Fx & portfolio adj.). Despite the cessation of marketing for older products such as Temik™, the insecticides business also registered a significant improvement of 10.2 percent (Fx & portfolio adj.). Sales of fungicides and herbicides grew by 10.5 and 6.2 percent, respectively (Fx & portfolio adj.).
By contrast, the BioScience business unit – which specializes in seed and traits – experienced a considerable drop in sales (Fx & portfolio adj. minus 20.9 percent). Business in the third quarter was weak particularly for canola and cotton seed in North America. However, double-digit growth rates were recorded for both crops over the first nine months. Sales of the Environmental Science business unit moved back by 3.2 percent (Fx adj.) in the third quarter.
EBITDA before special items of CropScience was up by 47.3 percent to EUR 165 million (Q3 2010: EUR 112 million). This increase resulted largely from significantly higher volumes and improved capacity utilization. The underlying EBITDA margin advanced to 12.0 percent (Q3 2010: 8.4 percent).
MaterialScience held back by raw material and energy costs
“At MaterialScience, the picture was mixed,” Dekkers continued. Sales of the high-tech materials business climbed by 3.9 percent (Fx & portfolio adj. 7.4 percent) in the third quarter, to EUR 2,768 million (Q3 2010: EUR 2,665 million). MaterialScience implemented selling price increases in all business units and regions. However, volumes as a whole were level year on year, with increases in the Latin America/Africa/Middle East and North America regions fully offsetting declines in Asia/Pacific.
Business with foam raw materials (Polyurethanes) improved by 7.1 percent (Fx & portfolio adj.). The high-tech plastics business (Polycarbonates) grew by a similar rate of 7.4 percent (Fx & portfolio adj.). Raw materials for coatings, adhesives and specialties advanced by 3.2 percent (Fx & portfolio adj.), while Industrial Operations grew sales by 23.8 percent (Fx & portfolio adj.).
EBITDA before special items of MaterialScience was down by 14.7 percent in the third quarter, to EUR 348 million (Q3 2010: EUR 408 million). This decline resulted mainly from higher raw material and energy costs, which were largely – but not fully – offset by selling price increases. Increases in project-related operating costs and downtime costs also had a negative impact on earnings.
Encouraging sales and earnings growth in the first nine months
Bayer achieved very encouraging increases in sales and earnings in the first nine months of 2011, with all three subgroups contributing to this performance. Sales for this period rose by 4.8 percent (Fx & portfolio adj. 6.8 percent) to EUR 27,337 million (9M 2010: EUR 26,076 million). EBIT increased by 31.4 percent to EUR 3,520 million (9M 2010: EUR 2,679 million), while EBITDA before special items advanced by 12.2 percent to EUR 6,072 million (9M 2010: EUR 5,412 million). Net income was up by 43.4 percent to EUR 2,073 million (9M 2010: EUR 1,446 million), while core earnings per share improved by 19.1 percent to EUR 3.86 (9M 2010: EUR 3.24).
Ongoing positive trend in the emerging markets
The emerging markets once again made a key contribution to sales growth. Bayer has defined these markets as the Asia/Pacific region (excluding Japan, Australia and New Zealand), Latin America, Eastern Europe, Africa and the Middle East. Sales in these countries advanced by 10.5 percent to EUR 9,746 million (Fx adj.) in the first nine months of 2011, with the third quarter accounting for EUR 3,331 million (Fx adj. plus 9.5 percent).
Dekkers also stressed the important progress that Bayer made in research and development in the third quarter, particularly with the anticoagulant Xarelto™ and the cancer drug Alpharadin™. In addition, a Phase III study with regorafenib in advanced colon cancer was terminated early due to positive interim results. Through 2013 Bayer plans to make a total of EUR 15 billion available for investing in its future, with research and development accounting for about two thirds of this amount.
EBITDA before special items predicted to exceed EUR 7.5 billion in 2011
“We can confirm the full-year sales and earnings forecast that we already raised in April,” Dekkers said. As previously announced, Bayer expects to raise sales in 2011 as a whole by between 5 and 7 percent (Fx & portfolio adj.). This corresponds to Group sales of between EUR 36 and 37 billion. This guidance is based on the exchange rates prevailing at the end of the third quarter of 2011. It remains Bayer’s aim to increase EBITDA before special items to more than EUR 7.5 billion. As before, the Bayer Group expects core earnings per share to improve by about 15 percent. Bayer continues to plan special charges of about EUR 0.5 billion in EBITDA for ongoing restructuring programs.
HealthCare plans to raise sales in 2011 by a low-single-digit percentage (previously: a low- to mid-single-digit percentage) on a currency- and portfolio-adjusted basis. Due especially to savings from its efficiency programs, EBITDA before special items is expected to increase by a mid-single-digit percentage to at least EUR 4.6 billion (previously: a small improvement). In the Pharmaceuticals segment, which the company believes will not yet resume growing with the market in 2011, sales are expected to remain largely unchanged or increase only slightly on a currency- and portfolio-adjusted basis (previously: low- to mid-single-digit percentage increase). Particularly in view of the structural measures, EBITDA before special items of Pharmaceuticals is predicted to rise by about 5 percent, improving the EBITDA margin before special items to about 30 percent (previously: raise the EBITDA margin before special items). In the Consumer Health segment, growth is expected to outpace the market on a currency- and portfolio-adjusted basis. Here, sales and EBITDA before special items are anticipated to increase by mid-single-digit percentages.
The CropScience business has continued to trend positively. In terms of sales, the subgroup aims as before to grow by a high-single-digit percentage (Fx & portfolio adj.) in 2011. In light of the good business performance in 2011 to date, it is planned to expand EBITDA before special items by more than (previously: about) 20 percent compared to the weak prior year.
MaterialScience anticipates higher sales in the fourth quarter, while EBITDA before special items is expected to come in below the prior-year period in view of continued increases in raw material and energy costs. For 2011 the subgroup anticipates that sales will grow by a high-single-digit percentage (Fx & portfolio adj.), with EBITDA before special items declining slightly to approximately EUR 1.3 billion (previously: growing at a higher rate than sales).
Other news from the department business & finance
Eppendorf and Neste forge strategic partnership to develop new line of renewable lab plastics
A sustainable choice for labs
Vulcan officially opened its Lithium Extraction Optimisation Plant
Europe’s first plant for fully domestic lithium chemicals production, to secure Europe’s lithium supply chain for Battery Electric Vehicle manufacturers
Spacetek Technology announces the successful closing of its Seed Financing Round
Time-of-flight mass spectrometers (TOF-MS) inspired by space technology
Start-up Better Basics Laborbedarf Wins First Place at the "Wiley Analytical Science Award 2024"
SmartRack® wins in the Separation, Laboratory Automation & Equipment Category
Hy2gen and Amogy Forge Strategic Partnership to Propel Ammonia-Powered Energy Solutions
Accelerate decarbonisation in the maritime sector
analytica 2024: Food analysis for sustainable nutrition
From PFAS to microplastics: focus on new harmful substances
BASF and SK On entered into an agreement to evaluate collaboration opportunities in the global lithium-ion battery market
Targeted collaboration around cathode active materials
Merck Confirms Forecast for Fiscal 2023 Despite Difficult Market Environment in Q3
Return to organic sales growth expected in 2024
Bayer: Third quarter below prior year as expected
Group outlook confirmed - By the end of next year, Bayer will remove multiple layers of management and coordination
Start-ups become changemakers – apply now!
ISC3 is looking for innovative solutions in the field of Sustainable Chemistry for textiles - Innovation Challenge 2024 endowed with 25,000 euros
HunterLab Spreads Its Vibrant Colors to Europe: Introducing 'HunterLab Europe'
Steering HunterLab Europe is none other than the Christian Jansen, who literally grew up in the color spectrophotometry world
Technology Group STRABAG invests € 100 million into battery and energy storage company CMBlu Energy
The ideal combination of technological and construction industry expertise to advance energy transition
Huber Kältemaschinenbau receives highest award at the "Großer Preis des Mittelstandes" (Grand Prix of Medium-Sized Businesses)
MAN Energy Solutions and Energy Dome Collaborate on CO2 Battery Technology
New strategic partnership to provide long-duration energy storage solution to facilitate the transition to net-zero
Merck to Return to Growth during Fiscal 2024
Transitional year 2023 managed well so far thanks to resilient business model
Startups with patents and trade marks are 10 times more successful in securing funding
Biotechnology sector leads in the use of patents and trade marks, with nearly half of the sector’s startups seeking these essential rights
Most read news
Plastic-eating bacteria turn waste into useful starting materials for other products
Microbial Upcycling of Waste PET
Microbes could help reduce the need for chemical fertilizers
A coating protects nitrogen-fixing bacteria: Start-up to commercialise coated bacteria for large-scale use in regenerative agriculture
New designs for solid-state electrolytes may soon revolutionize the battery industry
Scientists achieve monumental improvements in lithium-metal-chloride solid-state electrolytes
This is a battery
Two colored liquids bubbling through tubes: Is this what the battery of the future looks like?
Dow and Evonik announce startup of hydrogen peroxide to propylene glycol (HPPG) pilot plant
Innovative technology offer flexibility, lower costs, and a smaller environmental footprint
Inauguration of the world’s first pilot plant for the cost-efficient production of green methanol
Start-up C1 Green Chemicals AG and research partners develop fundamentally new production process
Converting PFAS “forever chemicals” into valuable compounds
Scientists develop a new method to incorporate harmful perfluoroalkenes into N-heterocyclic carbene ligands
Not so silver lining: Microplastics found in clouds could affect the weather
Low-altitude and denser clouds contained greater amounts of microplastics
Graphene's proton permeability: A switch for future energy technologies
This discovery could lead to the development of more efficient hydrogen fuel cells and solar water-splitting devices
Lithium-ion batteries are no longer the gold standard in battery tech
On the way to safer and more powerful energy sources
CO2-free hydrogen: BASF receives funding approval for 54-megawatt water electrolysis plant
Proton exchange membrane (PEM) electrolyzer expected to produce up to 8,000 metric tons of hydrogen per year
More news from our other portals
Bowel cancer: aspirin activates protective genes
Researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer.
Dunning-Kruger effect with muesli bars
Those who know the least consider themselves highly competent
Autonomous measuring instruments systematically detect new materials
A new algorithm measures materials libraries up to four times faster than before: It’s based on machine learning
New drug delivery system could reduce daily diabetes shots to just three a year
Dietary management drugs have transformed Type 2 diabetes care, but daily injection routines are challenging for some patients
Naked Clams: The New Superfood Sensation Emerging from the Depths
Researchers found Naked Clams contain almost twice the amount of Vitamin B12 as blue mussels and have developed an efficient way to farm them
Aston University technology to combat the not-so sweet practice of honey fraud
Light technology to be used to detect if honey is blended with cheap additions
Pushers, overcrowded trains and phone zombies
Sprite presents the world's first vending machine that responds to the things that bother Generation Z the most
Researchers discover new ultra strong material for microchip sensors
A material that doesn't just rival the strength of diamonds and graphene, but boasts a yield strength 10 times greater than Kevlar
How stem cells and immune cells communicate
Lisec Artz Award for Simon Haas: Groundbreaking discovery of an unknown protective mechanism against blood cancer from stem cells
Scientists use quantum biology, AI to sharpen genome editing tool
"This study represents an exciting advancement toward, understanding how we can avoid making costly ‘typos’ in an organism’s genetic code"
From the trough to the plate - digitally calculated
Computer program "ConTrans" estimates how much of an undesirable substance is transferred from animal feed to food
Viral Impostors: Breakthrough for Virus Research
The penetration of viruses into cells can now be tracked with unprecedented accuracy thanks to innovative design for pseudoviruses
Fatty acid factory filmed at work
High-resolution images provide new insights into cellular fatty acid production: Potential for medicine and biotechnology
Tönnies Group launches first nationwide "Meat Climate Platform"
100 guests at the Future Forum for Agriculture
Tracking down Environmental Toxins
Detection of per- and polyfluoroalkyl substances (PFAS) by interrupted energy transfer
The weight of pollution: exposure linked to obesity
Chronic exposure to environmental pollutants found to increase risk of cardiovascular disease
Are healthy foods automatically sustainable, too?
Perceptions about sustainability and healthy food choices are closely linked
Textbook knowledge turned on its head: 3-in-1 microorganism discovered
Newly multifunctional bacterial species
Could eating turkey ease colitis?
According to data in mice, extra tryptophan could reduce the risk of future colitis flares